Disease · MONDO_0002009
Comparisons in its trials381
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 381
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Vortioxetine Treatment vs SSRI Treatment: Number of Participants Who Experienced of Intracranial Hemorrhage in Total Follow-up Period | 2 of 22,827 | 25 of 124,950 | 147,777 | NCT05932407 | Trial comparisons |
| FSC Cohort vs AC Cohort: Number of Participants With Any Chronic Obstructive Pulmonary Disease (COPD)-Related Exacerbation | 200 of 1,078 | 674 of 2,923 | 4,001 | NCT01337336 | Trial comparisons |
| LY2216684 + SSRI Open-Label Phase vs Discontinuation Phase: serious adverse events | 13 of 600 | 0 of 472 | 1,072 | NCT01155661 | Trial comparisons |
| Period B Placebo and ADT (24 Weeks Randomised Treatment) vs Period B Brexpiprazole and ADT (24 Weeks Randomised Treatment): Full Functional Remission During the Randomised Treatment Period | 73 of 441 | 68 of 444 | 885 | NCT01838681 | Trial comparisons |
| Period B Placebo and ADT (24 Weeks Randomised Treatment) vs Period B Brexpiprazole and ADT (24 Weeks Randomised Treatment): Full Remission Sustained During the Randomised Treatment Period | 105 of 441 | 84 of 444 | 885 | NCT01838681 | Trial comparisons |
| Period B Placebo and ADT (24 Weeks Randomised Treatment) vs Period B Brexpiprazole and ADT (24 Weeks Randomised Treatment): Full Global Score Remission During the Randomised Treatment Period | 143 of 441 | 121 of 444 | 885 | NCT01838681 | Trial comparisons |
| Period B Placebo and ADT (24 Weeks Randomised Treatment) vs Period B Brexpiprazole and ADT (24 Weeks Randomised Treatment): Full Remission During the Randomised Treatment Period | 110 of 441 | 95 of 444 | 885 | NCT01838681 | Trial comparisons |
| Placebo and ADT vs Brexpiprazole and ADT: serious adverse events | 13 of 441 | 9 of 444 | 885 | NCT01838681 | Trial comparisons |
| Period B Placebo and ADT (24 Weeks Randomised Treatment) vs Period B Brexpiprazole and ADT (24 Weeks Randomised Treatment): Response at Week 6 During the Randomised Treatment Period | 76 of 440 | 82 of 442 | 882 | NCT01838681 | Trial comparisons |
| Period B Placebo and ADT (24 Weeks Randomised Treatment) vs Period B Brexpiprazole and ADT (24 Weeks Randomised Treatment): Remission at Week 24 in the Randomised Treatment Period | 198 of 440 | 176 of 442 | 882 | NCT01838681 | Trial comparisons |
| Period B Placebo and ADT (24 Weeks Randomised Treatment) vs Period B Brexpiprazole and ADT (24 Weeks Randomised Treatment): Remission at Week 6 During the Randomised Treatment Period | 46 of 440 | 53 of 442 | 882 | NCT01838681 | Trial comparisons |
| Period B Placebo and ADT (24 Weeks Randomised Treatment) vs Period B Brexpiprazole and ADT (24 Weeks Randomised Treatment): Response at Week 24 During the Randomised Treatment Period | 236 of 440 | 223 of 442 | 882 | NCT01838681 | Trial comparisons |
| TC-5214 vs Placebo: serious adverse events | 22 of 607 | 5 of 201 | 808 | NCT01152554 | Trial comparisons |
| Alcohol Abuse or Dependence vs Major Depression Only: serious adverse events | 8 of 138 | 23 of 536 | 674 | NCT00369746 | Trial comparisons |
| Esketamine Nasal Spray + Oral Antidepressant (AD) vs Quetiapine Extended Release (XR) + Oral AD: Number of Participants With Treatment-emergent Adverse Events (TEAEs) | 307 of 334 | 262 of 336 | 670 | NCT04338321 | Trial comparisons |
| Esketamine Nasal Spray + Oral Antidepressant (AD) vs Quetiapine Extended Release (XR) + Oral AD: Number of Participants With TEAEs of Special Interest | 223 of 334 | 140 of 336 | 670 | NCT04338321 | Trial comparisons |
| Esketamine Nasal Spray + Oral Antidepressant (AD) vs Quetiapine Extended Release (XR) + Oral AD: deaths from any cause | 1 of 334 | 1 of 336 | 670 | NCT04338321 | Trial comparisons |
| Esketamine Nasal Spray + Oral Antidepressant (AD) vs Quetiapine Extended Release (XR) + Oral AD: serious adverse events | 19 of 334 | 17 of 336 | 670 | NCT04338321 | Trial comparisons |
| Intervention vs Usual Care: deaths from any cause | 6 of 265 | 3 of 370 | 635 | NCT02655354 | Trial comparisons |
| Intervention vs Usual Care: serious adverse events | 15 of 265 | 13 of 370 | 635 | NCT02655354 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0002009/comparisons